Company intelligence / Profile preview

Foresite Capital

Larkspur, California, United Statesforesitecapital.com ↗

Ownership: Private
Employees: ~75
Development stage: Other

Overview

As an investor rather than a drug developer or biotech company per se. However:

Since 2011 has supported over 47 IPOs and 28 M&A events among its portfolio companies.
Portfolio includes multiple clinical-stage and commercial-stage biotechs.
Portfolio company drugs have achieved at least 58 FDA approvals as of June 2024.

Therapeutic areas: OncologyImmunologyRare DiseasesNeurologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibodyGene therapymRNA-based drugsCell therapy
Industry: Investors

Partnerships

ARCH Venture Partners (co-incubation of Xaira Therapeutics)Sequoia Capital (for specific investments like Xaira Therapeutics)Lightspeed Venture Partners (for specific investments like Xaira Therapeutics)

Beyond the preview

Go deeper on Foresite Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foresite Capital.